Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
The purpose of this study is to assess stereotactic radiosurgery (SRS) to treat people with small cell lung cancer (SCLC) who have been newly diagnosed with brain metastases (cancer that spread to the brain). SRS specifically targets a very small area of the body. By targeting the part of the brain where the cancer has spread, SRS may shrink the cancer without damaging healthy brain tissue.
The purpose of this study is to assess the safety of the investigational treatment REGN4018 alone and in combination with cemiplimab in women with ovarian, peritoneal, or fallopian tube cancer that has come back or gotten worse after previous treatment. REGN4018 is a type of drug called a bispecific antibody: it binds to two specific proteins (MUC16 and CD3) that may be involved in the growth and survival of cancer.
In this study, researchers are finding the highest dose of MQ710 to use safely in people with certain types of advanced cancer. The people in this study have solid tumors that came back or grew even after treatment. In a later part of the study, the researchers will assess MQ710 plus another drug called pembrolizumab.
The purpose of this study is to assess the safety and effectiveness of the investigational drug MORAb-202 in people with endometrial or ovarian cancer. MORAb-202 targets a protein called FRA on cancer cells and delivers eribulin (a chemotherapy drug) directly to these cells, which may slow or stop cancer growth. MORAb-202 is given intravenously (by vein).
The purpose of this study is to compare the effectiveness of lutetium (177Lu) edotreotide with standard therapies in people with neuroendocrine tumors of the stomach, intestines, or pancreas. Lutetium edotreotide binds to a protein on cancer cell surfaces called the somatostatin receptor and releases radiation to kill the cancer cell.
Researchers are assessing the cellular therapy lisocabtagene maraleucel (liso-cel) in people with primary central nervous system lymphoma (PCNSL). The people in this study have PCNSL that has not yet been treated. In addition, they cannot have autologous stem cell transplantation (ASCT). During ASCT, a patient's healthy, blood-forming cells are collected before treatment, stored, and returned after treatment with very strong chemotherapy.
Researchers want to find the best dose of LY4170156 to treat people with solid tumors. The people in this study have solid tumors that keep growing even after treatment. Their tumors also make a protein called FRA, which plays a role in cancer growth. The tumors treated in this study include:
The purpose of this study is to see if the combination of fianlimab, cemiplimab, and ipilimumab works well against melanoma. The people in this study have melanoma that is inoperable (cannot be taken out with surgery) or metastatic (spread). In addition, their cancer keeps growing even after treatment that included immunotherapy.
Researchers want to see how well a new combination of drugs works to treat low-grade serous ovarian cancer. The drugs are avutometinib, defactinib, and letrozole. The people in this study have ovarian cancer that cannot be completely removed with surgery.
Researchers want to see if adding IMNN-001 to standard treatment works well against advanced gynecologic cancers. The people in this study have newly diagnosed ovarian, fallopian tube, or primary peritoneal cancers.
